Search the Newsreel

Azenta (AZTA) Is Up 6.7% After Raising 2026 Guidance And Completing $50M Buyback – What’s Changed

Azenta, Inc. recently reported third-quarter 2026 results showing revenue of US$161.18 million versus US$143.86 million a year earlier, swung to a quarterly net income of US$2.46 million from a net loss, modestly raised full-year revenue guidance to US$613–US$618 million, and completed a US$50 million …

FMR LLC and Abigail Johnson disclose 15% Braze Inc (BRZE) ownership

FMR LLC and Abigail P. Johnson have reported a significant 15.0% ownership stake in Braze Inc.'s Class A common stock through a SCHEDULE 13G/A filing. FMR LLC beneficially owns 16,894,686.92 shares with sole voting power over 16,865,429 shares, while Abigail P. Johnson also beneficially …

Arrowstreet Capital Limited Partnership Buys New Position in Azenta, Inc. $AZTA

Arrowstreet Capital Limited Partnership has acquired a new position in Azenta, Inc. (NASDAQ:AZTA), purchasing 71,410 shares valued at approximately $1.51 million, representing about 0.15% of the company. This comes as Azenta reported strong quarterly earnings, exceeding analyst estimates for both EPS and revenue, though …

AstraZeneca Stock Leads 3 Cash Flow Picks Worth Watching In Europe

Azenta, Inc. 3Q 2026: Revenue $161.18M, EPS $0.05— 10-Q Summary

Azenta, Inc. reported strong third-quarter 2026 results, with revenue increasing 12% year-over-year to $161.18 million and diluted EPS reaching $0.05, a significant improvement from a loss in the prior year. The company returned to a net income of $2.46 million, driven by growth in …

Why Backblaze (BLZE) Is Up 47.4% After Hiking 2026 Outlook and Landing CoreWeave AI Deal

Backblaze (BLZE) saw its stock rise 47.4% after reporting strong Q2 2026 results, raising its full-year 2026 revenue guidance to US$172.0–174.0 million, and securing a US$335 million deal with CoreWeave for AI workloads. The company is highlighting its growing AI storage traction, particularly with …

AZEV4: Por que as ações da Azevedo & Travassos estão despencando hoje? - Investing.com Brasil

Is Backblaze (BLZE) Expensive As Q2 Earnings And The CoreWeave Deal Lift Interest?

Life Science Funding Weakness Hit Azenta’s (AZTA) Outlook

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Azenta, Inc. Stock 12‑Month Price Target Raised to $33.8, Implies 12% Upside

Azenta, Inc.'s stock price target has been increased from $27.8 to $33.8 by five analysts, implying a 12% potential upside based on its August 4th closing price. The consensus rating for the stock remains a "Buy" from six analysts. Investors can find more detailed …

Deal or No Deal, AstraZeneca Stock Is a Bargain

AstraZeneca's stock has become a potential bargain after recent investor concerns over a rumored megamerger with Bristol-Myers Squibb. Despite CEO Pascal Soriot's reputation for fostering growth through internal R&D and smaller, targeted acquisitions, the company's shares are down over 10% for the year and …

Azenta (AZTA) Stock Rallies on Revenue Strength as Cash Burn Lingers

Ahead of Beazer (BZH) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Backblaze (BLZE) Stock Price Jumps On 30% EBITDA Margin Breakthrough

Backblaze (BLZE) shares surged 27% after its Q2 2026 earnings report revealed a significant improvement in cash economics, with an adjusted EBITDA margin reaching 30% on $42.7 million in revenue. This performance highlights the company's progress toward profitability and strong B2 platform growth, including …

Azenta Inc (AZTA) (Q3 2026) Earnings Call Highlights: Organic Growth Surges 9% Amid Strategic ...

This article first appeared on GuruFocus. Total Revenue: $161 million, up 12% as reported and 9% organically year-over-year. Sample Management Solutions Revenue: $88 million, up 14% reported and 9% organically. Multiomics Revenue: $73 million, up 10% reported and 8% organically. Gross Margin: 46.2%, down …

Maze Therapeutics, Inc. (MAZE) CEO Coloma sells 34,501 shares via trusts

Maze Therapeutics, Inc. CEO Jason V. Coloma indirectly sold a total of 34,501 shares of common stock on August 3, 2026, through The Coloma 2021 Irrevocable Trust and the Coloma Family Trust. These sales, executed via a Rule 10b5-1 trading plan adopted in February …

Earnings call transcript: Azenta tops Q3 2026 estimates, shares edge higher

Azenta Q3 2026 EPS Tops Expectations, Revenue Up 12%

Azenta, Inc. reported strong Q3 2026 results, with Non-GAAP Diluted EPS of $0.16, significantly exceeding Wall Street's estimate of $0.12. The company's revenue rose 12.0% year-over-year to $161.2M, primarily driven by impressive organic growth of 9.0% and strong performance in its Sample Management Solutions …

AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation

Astra Zeneca logo on building ©Adobe Stock Images AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are "no discussions" between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The …

Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

By Maggie Fick and Sabrina Valle Aug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a ‌potential deal, a senior source close to the matter told ‌Reuters on Wednesday, quashing the prospect of a mooted mega merger …

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top …

AZN spikes 6% after report it denies AstraZeneca-BMS merger talks

Investing.com - AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, flatly quashing reports of a merger that would have created a pharmaceutical giant worth nearly …

AstraZeneca climbs Wednesday, outperforms market

Shares of AstraZeneca PLC (AZN) rose 2.52% to £120.36 on Wednesday, outperforming the FTSE 100 Index, which increased by 0.08%. The company's stock closed 23.49% below its 52-week high of £157.32.

AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface

AstraZeneca and Bristol Myers Squibb never held merger discussions and are not in talks now, a senior source close to the matter told Reuters on Wednesday. "There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there …

Empowered Funds LLC Acquires 119,822 Shares of Beazer Homes USA, Inc. $BZH

Empowered Funds LLC significantly increased its stake in Beazer Homes USA, Inc. by 555.9% in the first quarter, adding 119,822 shares to bring its total holdings to 141,377 shares valued at approximately $2.72 million. Despite this increased institutional ownership, with 85.65% of the stock …

Beazer Homes (BZH) Rallies 3.26% to $34.40, Testing Key Resistance - Leading Diagonal

Beazer Homes (BZH) Advances 2.28% to $34.07 as Homebuilder Sentiment Strengthens - Percent Below MA

Azenta, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:AZTA) 2026-08-05

AstraZeneca PLC Stock (AZN) Moved Up by 4.30% on Aug 5: A Full Analysis

Backblaze: Neoclouds And CoreWeave Have Rewritten Its Growth Trajectory (NASDAQ:BLZE)

Backblaze Shares Surge on Strong Q2 Results, Upbeat Guidance

Backblaze Inc. (NASDAQ: BLZE) shares surged after the company reported strong second-quarter 2026 financial results, exceeding market expectations, and provided optimistic forward-looking guidance. The cloud storage company's revenue increased by 18% year-over-year, driven by its B2 Cloud Storage segment, and it raised its full-year …

Azenta, Inc. (AZTA) SVP acquires 335 shares via 2017 stock purchase plan

Ephraim Starr, SVP, General Counsel & Secretary of Azenta, Inc. (AZTA), purchased 335 shares of common stock on July 31, 2026, at $24.1676 per share through the company's 2017 Employee Stock Purchase Plan. This transaction, which was exempt from Section 16(b), increased his direct …

Earnings Flash (AZTA) Azenta, Inc. Posts Q3 Adjusted EPS $0.16 per Share

Azenta, Inc. (AZTA) announced its Q3 adjusted EPS of $0.16 per share, surpassing FactSet's estimate of $0.11. The company also reported Q3 revenue of $161.2 million, exceeding FactSet's estimate of $149.3 million. This financial update indicates a stronger performance than anticipated by analysts for …

Azenta reports Q3 fiscal 2026: Revenue $161M, Adjusted EBITDA $18.5M, Non-GAAP EPS $0.16

Azenta (AZTA) reported its fiscal Q3 2026 results with revenue of $161.2 million and non-GAAP diluted EPS of $0.16. The company achieved an adjusted EBITDA of $18.5 million, representing an 11.4% margin, and noted 9% organic revenue growth year over year. Azenta also reiterated …

Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.

Azenta, Inc. reported its third-quarter financial results for fiscal year 2026, exceeding expectations with continued strength in recurring revenue and a modest improvement in Multiomics in North America. The company's revenue from continuing operations was $161 million, an increase of 12% year-over-year, and it …

Backblaze (NASDAQ:BLZE) Given New $25.00 Price Target at Oppenheimer